In millions, except per share items | Mar-31-23 | Dec-31-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 |
| 10-Q | 10-Q | 8-K | 10-Q | 10-Q | 8-K | 10-K | 10-Q |
Revenues | | | | | | | 397.9 | 376.1 |
Revenue growth | | | | | | | -20.6% | -33.1% |
Cost of goods sold | | | | | | | 296.9 | 288.0 |
Gross profit | | | | | | | 100.9 | 88.1 |
Gross margin | | | | | | | 25.4% | 23.4% |
Selling, general and administrative [+] | | | | | | | 138.4 | 134.4 |
Sales and marketing | | | | | | | 95.5 | 92.3 |
General and administrative | | | | | | | 42.9 | 42.1 |
Other operating expenses | | | | | | | 0.7 | |
EBITDA [+] | | | | | | | -10.5 | 1.8 |
EBITDA growth | | | | | | | -136.5% | -89.8% |
EBITDA margin | | | | | | | -2.7% | 0.5% |
Depreciation | | | | | | | 25.2 | 26.8 |
EBITA | | | | | | | -35.8 | -25.0 |
EBITA margin | | | | | | | -9.0% | -6.6% |
Amortization of intangibles | | | | | | | 2.4 | 1.8 |
EBIT [+] | | | | | | | -38.2 | -26.8 |
EBIT growth | | | | | | | 3827.1% | 106.4% |
EBIT margin | | | | | | | -9.6% | -7.1% |
Non-recurring items [+] | | | | | | | 0.0 | 18.8 |
Loss (gain) on sale of assets | | | | | | | 0.0 | 23.3 |
Interest expense | | | | | | | 16.0 | 11.8 |
Interest expense | | | | | | | 16.0 | 11.8 |
Other income (expense), net [+] | | | | | | | 26.1 | 24.8 |
Gain (loss) on sale of assets | | | | | | | -0.6 | |
Other | | | | | | | 19.7 | 24.8 |
Pre-tax income | | | | | | | -28.1 | -32.6 |
Income taxes | | | | | | | 13.6 | 14.8 |
Tax rate | | | | | | | -48.5% | -45.5% |
Net income | | | | | | | -42.2 | -48.0 |
Net margin | | | | | | | -10.6% | -12.8% |
|
Basic EPS [+] | | | | | | | ($2.40) | ($2.74) |
Growth | | | | | | | 9.5% | 28.1% |
Diluted EPS [+] | | | | | | | ($2.40) | ($2.74) |
Growth | | | | | | | 10.9% | 29.7% |
|
|
Shares outstanding (basic) [+] | | | | | | | 17.6 | 17.5 |
Growth | | | | | | | 2.4% | 2.1% |
Shares outstanding (diluted) [+] | | | | | | | 17.6 | 17.5 |
Growth | | | | | | | 1.2% | 0.8% |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |